Stoke Therapeutics, Inc. (STOK) is a pioneering biopharmaceutical company committed to addressing the underlying cause of severe genetic diseases by increasing protein production. The company was founded in 2014, and made its debut on the Nasdaq index in June 2019.
Headquartered in Bedford, Massachusetts, Stoke Therapeutics has developed a technology referred to as Targeted Augmentation of Nuclear Gene Output or TANGO. This innovative precision medicine platform is designed to treat a wide array of genetic diseases that are caused by mutations that lead to inadequate protein production within the body. Unlike traditional methods which mainly focus on repairing, replacing or bypassing the effects of a mutated gene, Stoke's platform aims to increase protein production from the remaining functional allele(s) to treat the root cause of the disease.
Stoke Therapeutics is primarily focused on diseases that impact the central nervous system (CNS), as well as on eye, liver and kidney diseases. One of the leading ongoing projects of the company is STK-001, a subtle, small molecule antisense oligonucleotide designed for the treatment of Dravet Syndrome, a severe form of epilepsy that begins in early childhood and impacts one in every 15,700 individuals.
Under the astute leadership of CEO Dr. Edward M. Kaye, the experienced team at Stoke Therapeutics is devoted to the development of life-changing, new medicines. Aside from making strides in medical research and development, Stoke is committed to maintaining a culture of dedication, respect, and compassion. Corporate responsibility, patient advocacy, and community involvement are integral parts of Stoke's mission.
Stoke Therapeutics has already garnered significant attention and investments from various sectors. With a solid scientific foundation and a therapeutic focus on areas of significant unmet medical need, Stoke Therapeutics stands as a promising enterprise in the field of precision genetic medicine. Through its cutting-edge technology and rigorous research efforts, the company is helping to shape a future where severe genetic diseases can be effectively treated or perhaps even cured.